Nachrichten zur Moderna Aktie

Moderna: Aktie bricht ein - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär": Andreas Deutsch vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Moderna vs. BioNTech: Kurssturz bei Moderna beeinflusst Konkurrenten

Die jüngsten Quartalszahlen von Moderna haben zu einem signifikanten Kurssturz der Aktie geführt, nachdem das Unternehmen einen Verlust von 3,33…

Meta Platforms, Ferrari, ConocoPhillips rise premarket; Arm, Moderna fall By Investing.com

Meta Platforms, Ferrari, ConocoPhillips rise premarket; Arm, Moderna fall…

Moderna cuts guidance on low EU sales, competitive vaccine environment in the U.S. By Investing.com

Moderna cuts guidance on low EU sales, competitive vaccine environment in the U.S.…

Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance…

Moderna’s stock slides 12% after it lowers full year sales guidance

Moderna Inc.’s stock tumbled 12% premarket Thursday, after the biotech cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter...…

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance…

Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue By Reuters

Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue…

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investors will likely focus on updates on Modernas (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The companys potential product…

Is Moderna Stock a Buy?

The biotech is proving that its not a pandemic stock.…

Flagship Pioneering Raises $3.6B for New Wave of Health, AI Innovation

Biotech investor Flagship Pioneering has raised $3.6 billion dollars for ventures in health, sustainability and AI. With $14 billion dollars…

Microsoft, Apple Drop OpenAI Board Plans | Bloomberg The Pulse 07/10/24

Microsoft and Apple dropped plans to take board roles at OpenAI in a surprise decision that underscores growing regulatory scrutiny of Big Tech’s…

Biotech investor behind Moderna raises $3.6bn for new ventures

Incubator Flagship Pioneering plans to finance and launch array of companies using AI for pharmaceutical development…

Play Likely Earnings Beat With 5 Top-Ranked Stocks

Top-ranked stocks Chewy (CHWY), Wingstop (WING), Moderna (MRNA), Tenet Healthcare (THC) and Kinross Gold (KGC) are likely to beat on…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Moderna, Inc. - MRNA

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac

mRNA specialist CureVac, which struggled to compete with the likes of Pfizer, Moderna and BioNTech, said it will focus on…

Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine

Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus,…

U.S. awards Moderna $176 million to produce bird flu vaccine

The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said…

Moderna Scores Federal Funding For mRNA Bird Flu Vaccine As Pandemic Fears Grow

Funding from U.S. biodefense agency Barda will support Moderna in developing an mRNA-based pandemic flu vaccine as fears grow the…

CHMP Endorses Modernas (MRNA) mRNA-based RSV Vaccine

If approved, the RSV vaccine will be Modernas (MRNA) second approved product in the European Union.…

Moderna: Really Strong Competition

…

Weekly Update: Rück- und Ausblick u.a. Abercrombie, Airbus, Bitcoin, Covestro, Moderna, Nike AG

Christian Hollendieck, Spezialist Aktien der ICF BANK AG, fasst die vergangene Handelswoche zusammen. Der Deutsche Leitindex bewegt sich weiter in…

IRW-News: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von Modernas RSV-Impfstoff mRESVIA(R)

IRW-PRESS: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von Modernas RSV-Impfstoff mRESVIA(R)CAMBRIDGE, MA…

IRW-News: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von Modernas RSV-Impfstoff mRESVIA(R)

IRW-PRESS: Moderna Inc.: Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Marktzulassung von…

Moderna: Erhöhtes Risiko für RSV-Schätzungen - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Evercore ISI: Cory Kasimov, Analyst von Evercore ISI, bestätigt sein Rating und Kursziel für die…

Moderna: Season 2 RSV-Daten am unteren Ende der Erwartungen - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co: Die Analysten von Jefferies & Co raten in einer aktuellen Aktienanalyse weiterhin…

Moderna massiv unter Druck – was ist da los?

Die Aktie von Moderna stand am Mittwoch massiv unter Druck. Mit einem Verlust von mehr als zehn Prozent war sie…

GSK and Moderna slide on RSV vaccine CDC updates

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine.…

GSK and Moderna RSV vaccine sell-off is overdone, say analysts

After GSK PLC (LSE:GSK, NYSE:GSK) shares fell sharply on the back of US authorities restricting doses of respiratory syncytial virus (RSV)…

Moderna Aktie stürzt ab - was ist los beim BioNTech-Konkurrenten?

In den letzten Monaten hat sich die Moderna Aktie weit besser entwickelt als der Aktienkurs des Konkurrenten BioNTech. Gestern aber…

Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data

Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second…

Moderna shares decline, RSV vaccine efficacy lags behind competitors By Investing.com

Moderna shares decline, RSV vaccine efficacy lags behind competitors…

Moderna RSV Vaccine Efficacy Sinks Over Time, CDC Documents Show

Moderna Inc. shares sank after new data showed the efficacy of its RSV shot fell sharply in the second year…

Moderna says its RSV shot is 50% effective after 18 months

In their clinical trials, GSKs RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and…

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…

Moderna: Kursziel angehoben

Charlotte (www.aktiencheck.de) - Rating-Update: Geoff Meacham, Analyst von BofA Securities, stuft die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol:…

Bei Moderna geht es jetzt ans Eingemachte. Seien Sie vorbereitet!

Eine Engelsgeduld brauchen momentan die Anteilseigner von Moderna. So beträgt das Minus im Vergleich zum Vorwochenschluss 2,17 Prozent. Mit Rücksetzern…

Moment Of Truth Approaches For Modernas RSV Vaccine

…

Modernas (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

Data from a late-stage study shows that Modernas (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared…

Moderna: Gewinne laufen lassen! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Moderna: RSV-Impfstoff mResvia im Fokus - Kursziel auf 179 USD erhöht - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Oppenheimer: Hartaj Singh, Analyst von Oppenheimer, stuft die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN:…

I’m relieved AI has come at the end of my investing career

Modern tech plays on our predilection for shortcuts – but it isn’t a quick-fix to getting rich…

Moderna price target raised at Oppenheimer after RSV vaccine approval By Investing.com

Moderna price target raised at Oppenheimer after RSV vaccine approval…

3 actions extraordinary people take to achieve what seems impossible, from the co-founder of Moderna

A mindset of "paranoid optimism" can help you tackle the most improbable challenges, according to Moderna co-founder and chairman Noubar…

Moderna president: Company outlook stabilizing thanks to new flu-COVID vaccine data

…

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

Data from a late-stage study shows that Modernas (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to…